MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $892.12 million. The enterprise value is $804.35 million.
| Market Cap | 892.12M |
| Enterprise Value | 804.35M |
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025, after market close.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 147.70 million shares outstanding. The number of shares has decreased by -3.82% in one year.
| Current Share Class | 147.70M |
| Shares Outstanding | 147.70M |
| Shares Change (YoY) | -3.82% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 1.61% |
| Owned by Institutions (%) | 45.11% |
| Float | 109.53M |
Valuation Ratios
The trailing PE ratio is 22.37 and the forward PE ratio is 24.16.
| PE Ratio | 22.37 |
| Forward PE | 24.16 |
| PS Ratio | 2.52 |
| Forward PS | 2.28 |
| PB Ratio | 4.40 |
| P/TBV Ratio | 5.18 |
| P/FCF Ratio | 13.81 |
| P/OCF Ratio | 13.62 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.81, with an EV/FCF ratio of 12.45.
| EV / Earnings | 20.02 |
| EV / Sales | 2.28 |
| EV / EBITDA | 12.81 |
| EV / EBIT | 14.81 |
| EV / FCF | 12.45 |
Financial Position
The company has a current ratio of 4.70, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.70 |
| Quick Ratio | 3.96 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.29 |
| Debt / FCF | 0.29 |
| Interest Coverage | 15.77 |
Financial Efficiency
Return on equity (ROE) is 22.29% and return on invested capital (ROIC) is 17.12%.
| Return on Equity (ROE) | 22.29% |
| Return on Assets (ROA) | 13.80% |
| Return on Invested Capital (ROIC) | 17.12% |
| Return on Capital Employed (ROCE) | 23.84% |
| Revenue Per Employee | $420,998 |
| Profits Per Employee | $48,006 |
| Employee Count | 837 |
| Asset Turnover | 1.43 |
| Inventory Turnover | 2.62 |
Taxes
In the past 12 months, MiMedx Group has paid $14.54 million in taxes.
| Income Tax | 14.54M |
| Effective Tax Rate | 26.67% |
Stock Price Statistics
The stock price has decreased by -15.64% in the last 52 weeks. The beta is 1.80, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -15.64% |
| 50-Day Moving Average | 6.76 |
| 200-Day Moving Average | 7.51 |
| Relative Strength Index (RSI) | 33.64 |
| Average Volume (20 Days) | 551,244 |
Short Selling Information
The latest short interest is 5.19 million, so 3.51% of the outstanding shares have been sold short.
| Short Interest | 5.19M |
| Short Previous Month | 5.35M |
| Short % of Shares Out | 3.51% |
| Short % of Float | 4.74% |
| Short Ratio (days to cover) | 5.93 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $352.38 million and earned $40.18 million in profits. Earnings per share was $0.27.
| Revenue | 352.38M |
| Gross Profit | 288.73M |
| Operating Income | 54.31M |
| Pretax Income | 63.47M |
| Net Income | 40.18M |
| EBITDA | 62.81M |
| EBIT | 54.31M |
| Earnings Per Share (EPS) | $0.27 |
Balance Sheet
The company has $106.43 million in cash and $18.66 million in debt, giving a net cash position of $87.77 million or $0.59 per share.
| Cash & Cash Equivalents | 106.43M |
| Total Debt | 18.66M |
| Net Cash | 87.77M |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 202.78M |
| Book Value Per Share | 1.37 |
| Working Capital | 157.49M |
Cash Flow
In the last 12 months, operating cash flow was $65.52 million and capital expenditures -$916,000, giving a free cash flow of $64.60 million.
| Operating Cash Flow | 65.52M |
| Capital Expenditures | -916,000 |
| Free Cash Flow | 64.60M |
| FCF Per Share | $0.44 |
Margins
Gross margin is 81.94%, with operating and profit margins of 15.41% and 11.40%.
| Gross Margin | 81.94% |
| Operating Margin | 15.41% |
| Pretax Margin | 15.47% |
| Profit Margin | 11.40% |
| EBITDA Margin | 17.82% |
| EBIT Margin | 15.41% |
| FCF Margin | 18.33% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.82% |
| Shareholder Yield | 3.82% |
| Earnings Yield | 4.50% |
| FCF Yield | 7.24% |
Analyst Forecast
The average price target for MiMedx Group is $12.50, which is 106.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.50 |
| Price Target Difference | 106.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MiMedx Group has an Altman Z-Score of 11.93 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.93 |
| Piotroski F-Score | 6 |